Arbutus Biopharma Corp represents values of innovation, collaboration, and dedication to improving the lives of patients. The company's corporate philosophy is centered around developing and commercializing transformative therapies for the treatment of infectious diseases and advancing the field of RNA interference (RNAi). Arbutus Biopharma Corp employs a rigorous scientific approach combined with strategic partnerships to drive drug discovery and development. With a focus on RNAi therapeutics, the company strives to address unmet medical needs and make a significant impact in the fight against viral diseases. Arbutus Biopharma Corp's commitment to excellence and forward-thinking solutions sets them apart in the biopharmaceutical industry.

Arbutus Biopharma Corp primarily operates in the United States and Canada. This global biopharmaceutical company focuses on developing a range of innovative therapeutic products to treat viral infections. With a strong presence in North America, Arbutus Biopharma Corp aims to address unmet medical needs through its cutting-edge research and development initiatives.

Arbutus Biopharma Corp has achieved several significant milestones in its history. The company successfully developed a proprietary lipid nanoparticle delivery system known as LNP, which has been extensively utilized for the delivery of RNA therapeutics. Additionally, Arbutus developed ARB-1467, an RNAi therapeutic product candidate for the treatment of chronic hepatitis B virus infection. The company also made progress in creating a pipeline of proprietary RNAi therapeutics targeting different diseases. Moreover, Arbutus has entered into collaborations and partnerships to further advance its research and development efforts. Through these achievements, Arbutus Biopharma Corp has demonstrated its dedication to pioneering innovative therapeutic solutions with the potential to make a substantial impact in the field of biopharmaceuticals.

Arbutus Biopharma Corp, formerly known as Tekmira Pharmaceuticals Corporation, is a Vancouver-based biopharmaceutical company focused on discovering, developing, and commercializing innovative antiviral therapies. Established in 2007, Arbutus Biopharma Corp has a rich history of scientific advancements and partnerships in the field of RNA interference (RNAi) technology. This technology aims to silence disease-causing genes, offering potential treatments for viral infections, including hepatitis B and C, as well as various liver and respiratory diseases. Through its commitment to research and development, Arbutus Biopharma Corp strives to transform the lives of patients worldwide by addressing critical unmet medical needs.

The main competitors of Arbutus Biopharma Corp in the market include Gilead Sciences, Inc., Alnylam Pharmaceuticals, Inc., and Vertex Pharmaceuticals Incorporated.

Arbutus Biopharma Corp is primarily active in the biopharmaceutical industry.

The business model of Arbutus Biopharma Corp revolves around researching and developing novel therapies for the treatment of viral diseases. The company focuses on discovering and advancing a pipeline of drug candidates that utilize RNA interference (RNAi) technology. By harnessing the power of RNAi, Arbutus Biopharma aims to silence or inhibit the genes responsible for viral replication, ultimately preventing the spread and progression of viral infections. This innovative approach shows promise in addressing diseases such as hepatitis B and hepatitis D. Arbutus Biopharma Corp aims to leverage its expertise and strategic collaborations to advance these therapies and improve patient outcomes.

Arbutus Biopharma KGV ir -7,22.

Arbutus Biopharma KUV ir 80,39.

AlleAktien kvalitātes vērtējums Arbutus Biopharma ir 5/10.

gaidāmā Arbutus Biopharma apgrozījums ir 6,73 milj. USD.

gaidāmā Arbutus Biopharma peļņa ir -74,92 milj. USD.

Arbutus Biopharma Corp is a bio-pharmaceutical company focused on the development of innovative therapies for the treatment of viral infections. The company operates in three main areas: therapeutics for the treatment of Hepatitis B virus (HBV), Lipid-Mediated Therapeutics™, and RNAi technology. In the HBV therapeutics segment, Arbutus Biopharma is developing a range of drugs aimed at completely eliminating HBV. The company focuses on the discovery and development of Toll-like receptor (TLR) antagonists and other antiviral drugs that harness the immune system to cure diseases. Arbutus Biopharma Corp has partnered with Roivant Sciences to support additional therapeutics in clinical development. In the Lipid-Mediated Therapeutics™ area, the company is developing drugs for the treatment of rare lung diseases and various infectious diseases. The company's platform utilizes non-viral, lipid-mediated delivery of mRNA transferred to cell cultures. Arbutus Biopharma Corp also includes RNAi technology in its product range. This technology utilizes RNA interference to accelerate the development process of RNA-based therapeutics. The company has several RNAi-based therapeutics in clinical development. Arbutus Biopharma Corp has entered into partnerships with various other companies to promote their developments and products. Additionally, the company offers contract development and manufacturing services to the pharmaceutical and biotechnology industries. Arbutus Biopharma Corp is a research and development-focused company. The company aims to develop drugs that meet the needs of the global healthcare sector and improve the lives of patients. The long-term vision of Arbutus Biopharma is to become a leading company in the healthcare industry.

Arbutus Biopharma izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Arbutus Biopharma vai uzņēmums nedod dividendes.

Arbutus Biopharma ISIN ir CA03879J1003.

Arbutus Biopharma WKN ir A14XMD.

Arbutus Biopharma simbols ir ABUS.

Pēdējo 12 mēnešu laikā Arbutus Biopharma maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Arbutus Biopharma plāno maksāt dividendes 0 USD apmērā.

Arbutus Biopharma pašreizējā dividendu rentabilitāte ir .

Arbutus Biopharma maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Arbutus Biopharma pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Arbutus Biopharma tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Arbutus Biopharma apmērā 0 USD, kas tika izmaksāta 11.07.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 11.07.2024..

Pēdējās dividendes izmaksa notika 11.07.2024..

Gadā 2023, Arbutus Biopharma izmaksāja 0 USD dividendes.

Arbutus Biopharma dividendes tiek izmaksātas USD.